193 related articles for article (PubMed ID: 34646386)
1. Effects of contrast-enhanced ultrasound treatment on neoadjuvant chemotherapy in breast cancer.
Rix A; Piepenbrock M; Flege B; von Stillfried S; Koczera P; Opacic T; Simons N; Boor P; Thoröe-Boveleth S; Deckers R; May JN; Lammers T; Schmitz G; Stickeler E; Kiessling F
Theranostics; 2021; 11(19):9557-9570. PubMed ID: 34646386
[No Abstract] [Full Text] [Related]
2. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
3. Perfusion-guided sonopermeation of neuroblastoma: a novel strategy for monitoring and predicting liposomal doxorubicin uptake
Bellary A; Villarreal A; Eslami R; Undseth QJ; Lec B; Defnet AM; Bagrodia N; Kandel JJ; Borden MA; Shaikh S; Chopra R; Laetsch TW; Delaney LJ; Shaw CM; Eisenbrey JR; Hernandez SL; Sirsi SR
Theranostics; 2020; 10(18):8143-8161. PubMed ID: 32724463
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound-Targeted Microbubble Destruction Enhances Inhibitory Effect of Apatinib on Angiogenesis in Triple Negative Breast Carcinoma Xenografts.
Hong D; Yang J; Guo J; Zhang Y; Chen Z
Anal Cell Pathol (Amst); 2021; 2021():8837950. PubMed ID: 33959473
[TBL] [Abstract][Full Text] [Related]
5. Targeted chemo-sonodynamic therapy treatment of breast tumours using ultrasound responsive microbubbles loaded with paclitaxel, doxorubicin and Rose Bengal.
Logan K; Foglietta F; Nesbitt H; Sheng Y; McKaig T; Kamila S; Gao J; Nomikou N; Callan B; McHale AP; Callan JF
Eur J Pharm Biopharm; 2019 Jun; 139():224-231. PubMed ID: 30959180
[TBL] [Abstract][Full Text] [Related]
6. Microbubble-enhanced ultrasound for the antivascular treatment and monitoring of hepatocellular carcinoma.
D'Souza JC; Sultan LR; Hunt SJ; Gade TP; Karmacharya MB; Schultz SM; Brice AK; Wood AKW; Sehgal CM
Nanotheranostics; 2019; 3(4):331-341. PubMed ID: 31687321
[No Abstract] [Full Text] [Related]
7. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
Walsh EM; Shalaby A; O'Loughlin M; Keane N; Webber MJ; Kerin MJ; Keane MM; Glynn SA; Callagy GM
Breast Cancer Res Treat; 2019 Feb; 174(1):1-13. PubMed ID: 30488345
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy Augmentation Using Low-Intensity Ultrasound Combined with Microbubbles with Different Mechanical Indexes in a Pancreatic Cancer Model.
Feng S; Qiao W; Tang J; Yu Y; Gao S; Liu Z; Zhu X
Ultrasound Med Biol; 2021 Nov; 47(11):3221-3230. PubMed ID: 34362582
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound-targeted microbubble destruction improved the antiangiogenic effect of Endostar in triple-negative breast carcinoma xenografts.
Jing Y; Xiu-Juan Z; Hong-Jiao C; Zhi-Kui C; Qing-Fu Q; En-Sheng X; Li-Wu L
J Cancer Res Clin Oncol; 2019 May; 145(5):1191-1200. PubMed ID: 30805775
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
Sella T; Gal Yam EN; Levanon K; Rotenberg TS; Gadot M; Kuchuk I; Molho RB; Itai A; Modiano TM; Gold R; Kaufman B; Shimon SP
Breast; 2018 Aug; 40():141-146. PubMed ID: 29800932
[TBL] [Abstract][Full Text] [Related]
11. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
[TBL] [Abstract][Full Text] [Related]
12. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
Ueno T; Kitano S; Masuda N; Ikarashi D; Yamashita M; Chiba T; Kadoya T; Bando H; Yamanaka T; Ohtani S; Nagai S; Nakayama T; Takahashi M; Saji S; Aogi K; Velaga R; Kawaguchi K; Morita S; Haga H; Ohno S; Toi M
BMC Med; 2022 Apr; 20(1):136. PubMed ID: 35462552
[TBL] [Abstract][Full Text] [Related]
13. Contrast-enhanced ultrasound (CEUS) in assessing early response among patients with invasive breast cancer undergoing neoadjuvant chemotherapy.
Saracco A; Szabó BK; Tánczos E; Bergh J; Hatschek T
Acta Radiol; 2017 Apr; 58(4):394-402. PubMed ID: 27461224
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
[TBL] [Abstract][Full Text] [Related]
15. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
16. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
Pandy JGP; Balolong-Garcia JC; Cruz-Ordinario MVB; Que FVF
BMC Cancer; 2019 Nov; 19(1):1065. PubMed ID: 31703646
[TBL] [Abstract][Full Text] [Related]
17. Quantitative contrast-enhanced ultrasound evaluation of pathological complete response in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy.
Wan CF; Liu XS; Wang L; Zhang J; Lu JS; Li FH
Eur J Radiol; 2018 Jun; 103():118-123. PubMed ID: 29803376
[TBL] [Abstract][Full Text] [Related]
18. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.
Sharma P; Stecklein SR; Yoder R; Staley JM; Schwensen K; O'Dea A; Nye L; Satelli D; Crane G; Madan R; O'Neil MF; Wagner J; Larson KE; Balanoff C; Kilgore L; Phadnis MA; Godwin AK; Salgado R; Khan QJ; O'Shaughnessy J
JAMA Oncol; 2024 Feb; 10(2):227-235. PubMed ID: 37991778
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
Humbert O; Riedinger JM; Vrigneaud JM; Kanoun S; Dygai-Cochet I; Berriolo-Riedinger A; Toubeau M; Depardon E; Lassere M; Tisserand S; Fumoleau P; Brunotte F; Cochet A
J Nucl Med; 2016 Nov; 57(11):1707-1712. PubMed ID: 27103025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
